Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by MAIA Biotechnology, Inc.

< Previous 1 2 3 Next >
MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Participate in the 36th Annual ROTH Conference
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology and Nationwide Children’s Hospital Announce Presentation of THIO’s Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces $4 Million Registered Direct Offering
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Present Latest Findings for Second Generation THIO Program at Turkish Biochemical Society’s International Biochemistry Congress 2023
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reveals New Data Showing THIO’s Potent Anticancer Activity in Aggressive Pediatric Brain Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial as Efficacy Is Observed in Dosed Patients
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Potent Anticancer Activity of THIO in Gliomas
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Share Repurchase Program
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Updates on Preliminary Survival Data for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Updates in Enrollment in Phase II Clinical Trial: THIO-101 Has Enrolled 29 Patients
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Files Second Patent For New Telomere-Targeting Molecules Program
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports First Quarter 2023 Financial Results and Provides Corporate Update
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology, Inc. Announces Closing of Public Offering
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology, Inc. Announces Pricing of Public Offering
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.